

University of Groningen



Risk factors for Nontuberculous Mycobacteria Infections in Solid Organ Transplant recipients

Mejia-Chew, Carlos; Carver, Peggy L; Rutjanawech, Sasinuch; Camargo, Luis F Aranha; Fernandes, Ruan; Belga, Sara; Daniels, Shay Anne; Mueller, Nicolas J; Burkhard, Sara; Theodoropoulos, Nicole M

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

DOI: 10.1093/cid/ciac608

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date: 2023

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Mejia-Chew, C., Carver, P. L., Rutjanawech, S., Camargo, L. F. A., Fernandes, R., Belga, S., Daniels, S. A., Mueller, N. J., Burkhard, S., Theodoropoulos, N. M., Postma, D. F., van Duijn, P. J., Fariñas, M. C., González-Rico, C., Hand, J., Lowe, A., Bodro, M., Vanino, E., Cruz, A. F., ... López-Medrano, F. (2023). Risk factors for Nontuberculous Mycobacteria Infections in Solid Organ Transplant recipients: a multinational case-control study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, *76*(3), Article ciac608. Advance online publication. https://doi.org/10.1093/cid/ciac608

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverneamendment.

Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Risk Factors for Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients: A Multinational **Case-Control Study**

Carlos Mejia-Chew,^{1,®} Peggy L. Carver,² Sasinuch Rutjanawech,¹ Luis F. Aranha Camargo,³ Ruan Fernandes,³ Sara Belga,⁴ Shay-Anne Daniels,⁴ Nicolas J. Müller,⁵ Sara Burkhard,⁵ Nicole M. Theodoropoulos,⁶ Douwe F. Postma,⁷ Pleun J. van Duijn,⁸ María Carmen Fariñas,⁹ Claudia González-Rico,^{9,10} Jonathan Hand,¹¹ Adam Lowe,¹¹ Marta Bodro,¹² Elisa Vanino,^{13,14} Ana Fernández Cruz,¹⁵ Antonio Ramos,¹⁵ Mateja Jankovic Makek,¹⁶ Ribal Bou Mjahed,¹⁷ Oriol Manuel,¹⁷ Nassim Kamar,¹⁸ Antonia Calvo-Cano,¹⁹ Laura Rueda Carrasco,¹⁹ Patricia Muñoz,²⁰ Sara Rodríguez,²⁰ Sandra Pérez-Recio,²¹ Núria Sabé,²¹ Regino Rodríguez Álvarez,²² José Tiago Silva,^{23,24} Alessandra Mularoni,²⁵ Elisa Vidal,²⁶ Juana Alonso-Titos,²⁷ Teresa del Rosal,²⁸ Annika Y. Classen,^{29,30} Charles W. Goss,¹ Mansi Agarwal,¹ and Francisco López-Medrano^{23,24}; on behalf of the EMOTE study group

¹Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA; ²College of Pharmacy, The University of Michigan, Ann Arbor, Michigan, USA; ³Hospital Israelita Albert Einstein, São Paulo, Brazil; ⁴Division of Infectious Diseases, Department of Medicine, The University of British Columbia Faculty of Medicine, Vancouver, Canada; ⁵Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland; ⁶Department of Medicine, Division of Infectious Diseases & Immunology, UMass Chan Medical School, Worchester, Massachusetts, USA; ⁷Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen, The Netherlands; ⁸Department of Clinical Microbiology, University Medical Center Groningen, The Netherlands; ⁹Infectious Diseases Service, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Spain; ¹⁰CIBERINFEC (CB21/13/00068), ISCIII, Madrid, Spain; ¹¹Department of Infectious Diseases, Ochsner Medical Center, New Orleans, Louisiana, USA; ¹²Hospital Clinic Barcelona, Spain; ¹³Infectious Diseases Unit, IRCCS Policlinico Sant'Orsola, University of Bologna, Italy;¹⁴Infectious Diseases Unit, Ravenna Hospital, AUSL Romagna, Italy;¹⁵Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain; 16 University Hospital Center Zagreb, University of Zagreb School of Medicine, Croatia; 17 Lausanne University Hospital (CHUV), University of Lausanne, Switzerland; ¹⁸Department of Nephrology and Organs Transplantation, Toulouse Rangueil University, INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), Paul Sabatier University, Toulouse, France; 19/Infectious Disease Department, University Hospital Badajoz, Badajoz, Spain; 20/Hospital Gregorio Marañón, Madrid, Spain; 21/Tuberculosis Unit, Department of Infectious Diseases, Bellvitge University Hospital Bellvitge University Hospital-Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain; 22Hospital Universitario Cruces, Barakaldo, Spain; 23Unit of Infectious Diseases, University Hospital 12 de Octubre, Instituto de Investigación del Hospital 12 de Octubre (imas12), School of Medicine, Universidad Complutense, Madrid, Spain; 24Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC; CB21/13/00009), Instituto de Salud Carlos III, Madrid, Spain; ²⁵IRCC-ISMETT, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy; ²⁶Infectious Diseases Service, Reina Sofia University Hospital, Madrid, Spain; ²⁷Nephrology Department, Hospital Regional Universitario de Málaga, Málaga, Spain; 28 Pediatric Infectious and Tropical Diseases Department, Hospital Universitario La Paz, Madrid, Spain; 29 Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, University of Cologne, Cologne, Germany; and ³⁰German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany

Background. Risk factors for nontuberculous mycobacteria (NTM) infections after solid organ transplant (SOT) are not well characterized. Here we aimed to describe these factors.

Methods. Retrospective, multinational, 1:2 matched case-control study that included SOT recipients \geq 12 years old diagnosed with NTM infection from 1 January 2008 to 31 December 2018. Controls were matched on transplanted organ, NTM treatment center, and post-transplant survival greater than or equal to the time to NTM diagnosis. Logistic regression on matched pairs was used to assess associations between risk factors and NTM infections.

Results. Analyses included 85 cases and 169 controls (59% male, 88% White, median age at time of SOT of 54 years [interquartile range {IQR} 40-62]). NTM infection occurred in kidney (42%), lung (35%), heart and liver (11% each), and pancreas transplant recipients (1%). Median time from transplant to infection was 21.6 months (IQR 5.3-55.2). Most underlying comorbidities were evenly distributed between groups; however, cases were older at the time of NTM diagnosis, more frequently on systemic corticosteroids and had a lower lymphocyte count (all P < .05). In the multivariable model, older age at transplant (adjusted odds ratio [aOR] 1.04; 95 confidence interval [CI], 1.01-1.07), hospital admission within 90 days (aOR, 3.14; 95% CI, 1.41-6.98), receipt of antifungals (aOR, 5.35; 95% CI, 1.7-16.91), and lymphocyte-specific antibodies (aOR, 7.73; 95% CI, 1.07-56.14), were associated with NTM infection.

Conclusions. Risk of NTM infection in SOT recipients was associated with older age at SOT, prior hospital admission, receipt of antifungals or lymphocyte-specific antibodies. NTM infection should be considered in SOT patients with these risk factors. Keywords. nontuberculous mycobacteria; solid organ transplant; risk factors; NTM.

Clinical Infectious Diseases[®] 2023:76(3):e995-e1003

Nontuberculous mycobacteria (NTM) are environmental microorganisms that cause pulmonary, extrapulmonary, or disseminated disease [1]. The incidence of NTM pulmonary disease (NTM-PD), the most common presentation, has been increasing in the last decades [2, 3]. In many countries, prevalence of NTM-PD has surpassed that of tuberculosis [4].

Received 28 March 2022; editorial decision 18 July 2022; published online 26 July 2022 Correspondence: C. Mejia-Chew, Washington University in St Louis. 4523 Clayton Ave, Campus Box 8051. St Louis, MO 63110, USA. (carlosmejia@wustl.edu).

[©] The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com https://doi.org/10.1093/cid/ciac608

In solid organ transplant (SOT) recipients the use of immunosuppressant's to prevent graft rejection, pose a particular increased risk of infection [5, 6]. Although NTM infections in SOT are thought to be rare, the true incidence is unknown due to the lack of mandatory reporting for NTM. The estimated frequency of NTM infection in SOT varies by the transplanted organ, highest in lung (0.46–14%), followed by heart (0.24–2.8%), kidney (0.16–0.38%), and liver recipients (0.04%) [7, 8]. There are no estimates for pancreatic or small bowel recipients [9].

Furthermore, distinguishing between colonization and infection is often difficult. In a single-center study over a 10-year period, 1.5% of SOT recipients had positive cultures, but 82% of those NTM isolates represented colonization; hence, only 0.26% had disease [10]. Knoll et al found that airway colonization in lung transplant was not associated with decreased median post-transplant survival [11].

Risk factors for NTM infection in SOT recipients are not well characterized. A case-control study found that lung transplant recipients and those with biopsy-proven acute rejection were at highest risk of NTM disease [12]. Katsolis et al, looking exclusively at lung transplant recipients, found increased risk of disease in those with underlying cystic fibrosis, receipt of anti-thymocyte globulin, and NTM infection before transplant [13]. Another study of lung transplant recipients found that almost a quarter had pre-transplant infection with the same NTM species [14]. Prior infection was also described by Huang et al as a risk factor for infection following transplantation, as well as receipt of a single lung transplant [15]. Shah et al found increased risk of NTM infection after lung transplantation in Black Americans and patients with high-risk cytomegalovirus (CMV) mismatch [8]. Because previous studies have been single center, limited to lung transplant recipients or a particular NTM species, the aim of this multinational study was to describe the clinical characteristics and risk factors for developing NTM infections after SOT.

METHODS

Study Design and Setting

Retrospective, multinational, 1:2 matched case-control study including SOT recipients diagnosed with NTM infection between 1 January 2008 and 31 December 2018. We established a multisite collaboration with 25 centers from 10 countries in Europe and America to study the epidemiology, clinical characteristics, management, and outcomes of transplant recipients with NTM disease (EMOTE study). All sites followed research regulations and obtained approval from their local institutional review board. Personal health information collected was compliant with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and European General Data Protection Regulation (GDPR) data privacy laws; hence, informed consent was waived.

Participants

We included patients \geq 12 years of age who had received a SOT prior to the NTM infection and met the case definition. NTM-PD needed to fulfil clinical, radiological, and microbiological diagnostic criteria recommended by guidelines during the study period [16, 17]. NTM-PD was also established if the managing physician considered treatment was warranted based on positive cultures. Extrapulmonary disease required at least 1 positive culture deemed clinically relevant and meriting therapy. Systemic disease required involvement of \geq 2 noncontiguous organs. For each case we selected 2 controls matched on (1) same transplanted organ in the same institution as the case; (2) no NTM disease up to the date of inclusion; (3) had survived at least as long as the case had prior to the NTM diagnosis.

Variables and Definitions

Date of diagnosis was the collection date of the culture(s) that met case definition (ie, index date). For controls, a corresponding date was chosen based of their matched case's date of diagnosis (ie, if NTM infection develops 500 days posttransplantation, the control's "index date" is 500 days after transplantation). We collected demographic characteristics, comorbidities in the year prior to the index date, transplant characteristics (underlying disease leading to transplantation, date of transplant, donor age, and post-transplant need for intensive care unit [ICU] admission, mechanical ventilation, renal replacement therapy, CMV disease, and organ rejection), concomitant infections, and laboratory data (white blood cell count, neutrophil and lymphocyte counts, platelets, hemoglobin, hematocrit, creatinine, transaminases, total bilirubin, lactate dehydrogenase); closest to the index date but limited to 6 months prior to or after that date. We also collected use of immunosuppressive therapy, hospitalizations, receipt of chemotherapy or radiotherapy; all within 90 days of the index date; a period based on previous data linking risk of NTM disease to acute organ rejection and aimed at identifying augmented immunosuppression. Concomitant infection was defined as a clinical syndrome with supporting microbiological data and warranting therapy. Age at transplant and age at diagnosis refer to the age of the patient at the time of SOT and at the time NTM infection diagnosis, respectively.

For cases, we recorded clinical symptoms, microbiological characteristics (NTM species and susceptibilities, smear positivity, pathology biopsy results, time to culture positivity, number of positive cultures, and specimen source). Abiding GDPR rules, date of transplant was time zero and all other events were captured as time in days from it.

Data were collected and managed using REDCap (Research Electronic Data Capture), a secure, web-based software platform electronic data capture tools, hosted at Washington University in St. Louis, Missouri, USA, and protected by its server's firewalls [18].

Statistical Analysis

To assess between-group differences in demographics, transplant characteristics, comorbidities, risk factors, concomitant infections, and laboratory values we used bivariate conditional regression, conditional on matched pairs. To identify risk factors for NTM disease, we used a multivariable conditional logistic-regression approach. Variables were selected using a forward-stepwise approach with entry criteria of P < .10, and variables were retained for P values < .05. Variables with > 5% missing data were not considered for inclusion in the multivariable models. Additionally, clinically important variables supported by previous studies and a priori expectations (underlying lung disease and lymphocyte count) were included in all models. Lymphocyte count was an exploratory variable considered relevant to include given the biological plausibility of well-described increased risk of NTM infection in those with poor T-cell function, and higher risk of pulmonary reinfection in those with lymphopenia [5, 19]. All statistical tests were 2-tailed, and P values < .05 were considered significant. All statistical analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, North Carolina, USA).

RESULTS

We included 85 cases of NTM infection from 10 Spanish (n = 19), 4 American (n = 37), 3 Swiss (n = 7), 2 Italian (n = 19)3), 1 Brazilian (n=6), 1 Canadian (n=5), 1 Dutch (n=4), 1 French (n=2), and 1 Croatian (n=2) centers; and 169 matched controls. For 1 case, only 1 control was available. Overall, 59% of the participants were male, 88% were White, and median age at transplant was 54 years (interquartile range [IQR] 40-62). The most frequent organ transplanted was kidney (42%), followed by lung (35%), heart (11%), liver (11%), and pancreas (1%). Distribution of demographic and transplant characteristics were similar between groups except for older age at the time of transplant (58 vs 52 years; P = .009) and time of NTM diagnosis (61 vs 55 year; P = .014) in cases compared to the controls (Table 1). Comorbidities were similarly distributed between groups apart from cancer (11.8% vs 4.1%; P = .029) that was significantly more frequent in the cases (Table 1).

Characteristics of NTM Infections in SOT Recipients

The most common NTM species isolated in SOT were *Mycobacterium avium* complex (MAC) (n = 27, 31.7%), *Mycobacterium abscessus* complex (MABSC) (n = 18, 21.2%), and *Mycobacterium fortuitum* (n = 9, 10.5%) (Table 2 and Supplementary Table 1). The number of NTM infections in SOT due to slowly growing mycobacteria (SGM) and rapidly growing mycobacteria (RGM) was similar (56% vs 44%, respectively), and the most common sites of NTM infection were pulmonary (n = 49, 57.6%), skin and soft tissues (n = 18, 21.2%),

endovascular and disseminated disease (n = 14, 16.5%), and other (n = 4, 4.7%). In those with endovascular and disseminated disease (n = 14), organ involvement included the lungs (n = 8), the gastrointestinal tract (n = 7), lymph nodes (n = 3), endovascular (n = 4), bone and joint (n = 2), and skin and soft tissues (n = 2); only1 case had a central-line associated bloodstream infection due to an RGM. Other sites of infection included one case each of mediastinitis, empyema, colitis, and kidney allograft infection (Table 2). The majority of those with pulmonary NTM (n = 49) were diagnosed with specimens obtained through bronchoscopy (n = 38, 77%). In those with disseminated disease (n = 14), only 5 (35%) had positive blood cultures. Overall, 46% of specimens tested had acid-fast bacilli on smears and NTM polymerase chain reaction (PCR) DNA sequencing was done in 34% of the samples.

Median [IQR] time from transplant to infection was 21.6 months [5.3–55.2] and was longer in kidney and liver (34.7 months [17.0–64.0] and 21.6 months [7.0–64.0], respectively) than in lung or heart recipients (11.3 months [4.2–31.0] and 3.5 months [2.9–67.1], respectively). For extrapulmonary NTM, median [IQR] time to diagnosis was longer than for pulmonary disease (30.6 months [9.4–61.8] vs 20.2 months [4.6–51.0], respectively), but similar between SGM and RGM (Figure 1). Only 11 (13%) cases had a prior positive culture that was considered colonization, but none of the NTM species identified were the same species that caused disease.

The most common symptoms in patients with pulmonary NTM were cough (68%), dyspnea (39%), fever (35%), and fatigue (30%). In patients with extrapulmonary NTM infection, almost half (46%) had skin lesions, and only 25% had fever. However, although fever was frequent in those with disseminated disease (n = 10/14, 71%), only 1 case had skin lesions (7%). Most patients with extrapulmonary disease (60%) had protean clinical manifestations that varied by site of infection.

Risk Factors for NTM Disease

Compared to the controls, cases had more hospitalizations (32% vs 18%; P = .006) and were more commonly diagnosed with another infection (36% vs 5%; P < .001) in the previous 90 days. Among those with a concomitant infection, pneumonia (32% vs 11%; P < .001) and urinary tract infection (11% vs 3%; P = .016) were significantly more frequent in cases than in controls (Supplementary Table 2). In cases, the most frequent concomitant infection was fungal (15%), followed by bacterial (13%), and viral (8%). At the time of diagnosis, cases were more frequently receiving systemic corticosteroids (85% vs 75%; P = .027) and had a lower median lymphocyte count compared to controls ($0.8-10^3/\mu$ L vs $1.2-10^3/\mu$ L; P < .001). Use of other immunosuppressant's within 90 days and suspected or confirmed organ rejection prior to the diagnosis was not different between cases and controls (Table 1). Underlying reasons

Table 1. Baseline Characteristics of Solid Organ Transplant Recipients With Nontuberculous Mycobacterial Disease and Their Matched Controls

Clinical Characteristics n = 190 (%) n = 190 (%) CPI 409% (C) PVAlue Median (ICP) tops at dispnosis in years 01 (17-60) 55 (14-64) 1.03 (10-106) 014 Frenzia sex 35 (41) 68 (40) 1.06 (50-180) 62 (23-1.06) 57 12 Transplant diamateristics 7282 (88) 1380/155 (80) 62 (23-1.06) 57 12 Transplant diamateristics 9 (11) 18 (11) Lang 30 (23) 69 (243) Median (12) 30 (23) 69 (243) Median (12) 30 (23) 69 (243)		Cases	Controls		
Democryatic characteristics Democryatics 01147-08 Des 143-043 Des 143-043 <thdes 143-0<="" th=""><th>Clinical Characteristics</th><th>n=85 (%)</th><th>n = 169 (%)</th><th>OR (95% CI)^a</th><th>P Value^b</th></thdes>	Clinical Characteristics	n=85 (%)	n = 169 (%)	OR (95% CI) ^a	P Value ^b
Medan (10R) age at diagnosis in years 61 (47-06) 56 (41) 66 (40) 1.06 (59-1.89) 843 When nace 72(82 (88) 138(715 (68) 52 (23-1.65) 512 Targefant dravatoristics. 72(82 (88) 138(715 (68) 52 (23-1.65) 512 Targefant dravatoristics. 9 (11) 18 (11) Komey 36 (62) 60 (56) Komey 36 (12) 24 (43) Modan (10R) age at transplant to years 58 (44-58) 52 (23-51) 1.03 (1.0.1-1.06) 0.09 Modan (10R) age at transplant to years 58 (44-56) 38 (23-50) 1.02 (59-1.05) 1.02 (59-1.05) 1.02 (59-1.05) 1.02 (59-1.05) Pacta targutant transplant to pace-match therapy 1.26 (27) 1.00 (140-1.05) Modan (10R) domo pain wars 3.0 (27) 2.0 (20-1.12) 1.02 (59-2.17) Der/R - 1.07/2 (24)	Demographic characteristics				
Fernale case 35 (41) 06 (40) 1.00 (159-118) 48/3 Vinte acc 72/22 (28) 130/156 (68) 52 (23-5) 52 Tensplant tampalantion* 91111 18 (11) Heart 91111 18 (11) Kohey 05 (42) 72 (40) Liver 91111 17 (10)	Median [IQR] age at diagnosis in years	61 [47–66]	55 [43–64]	1.03 (1.01–1.06)	.014
When one 72/82 (8) 136/155 (8) 02 (23-1.05) 5.12 Type of solid organ transplantation" Image intransplantation (1) Image (1) Image (1) Image (Female sex	35 (41)	68 (40)	1.06 (.59–1.89)	.843
Transplant characteristics Type of solid orge introgeneration"	White race	72/82 (88)	136/155 (88)	.62 (.23–1.65)	.512
Type of solid organ transplantation" Image 9 (11) 18 (11) Ling 30 (35) 60 (36) Kidney 36 (42) 72 (43) Faincreas 1 (1) 2 (11) Faincreas 1 (1) 2 (11) Moden [IOR] age at transplant in years 86 (4-63) 52 (28-61) 103 (10-106) .005 Moden [IOR] founder of transplant cage in years 3 (25-50) 31 (23-90) 1.02 (39-106) .047 Moden [IOR] founder of pair years 3 (25-50) 31 (23-02) 1.01 (24-282) .813 CMV scrological status 1.772 (24) 26 (127 (21) 1.00 (48-245) .836 D-/R + 1.377 (24) 26 (127 (21) 1.00 (48-245) .836 D-/R + 1.377 (24) 26 (127 (21) 1.00 (48-245) .836 D-/R + 1.377 (24) 26 (127 (21) 1.00 (48-2.45) .846 D-/R	Transplant characteristics				
Heart 9 (11) 16 (11) Lung 30 (35) 60 (36) Kinkey 36 (42) 72 (43) Percosa 1 (1) 2 (1) Madian [104] age at transplant loyers 58 [44–63] 52 (39–61] 1.03 (101–1.06) .009 Madian [104] insome of transplants 111–11 111–11 117.1 12.1 Madian [104] insome of transplant to transplant (01 stay in days 3 [5–6] 32 (23–61) 1.03 (100–1.06) .077 Posttransplant mechanical variabilitito 32.77 (24) 20.476 1.03 (100–1.06) Posttransplant mechanical variabilitito 32.77 (24) 20.476 1.03 (105–3.77) .483 Charachical mechanical variabilitito 32.77 (24) 20.476 (14) 1.10 (148-3.48) D-/R 1.077 (24) 20.172 (10) 1.03 (145–3.73) .866 D-/R 1.01 (24.738) 1.01 (24.738) D-/R	Type of solid organ transplantation ^c				
Lung 30 (35) 60 (36) Marker 36 (42) 72 (43) Liver 9 (11) 17 (10) Peacrase 1 (1) 2 (1) Median [IGR] age at transplant in years 58 [44–63] 52 [39–61] 1.03 (1.01–1.06) .009 Median [IGR] incomptent or page in years 4.35 [26–56] 38 [23–50] 1.02 (39–1.05) .147 Median [IGR] incomptent or page in years 4.35 [26–56] 38 [23–50] 1.02 (39–1.05) .147 Median [IGR] incomptent or page in years 32779 (4) 62/166 (40) 1.12 (44–2.82) .813 CVV servidgical strus - 1.772 (24) 2.6(771 (21) 1.09 (48–2.45) .866 D+R - 1.772 (24) 2.4(721 (21) 1.00 (38–2.47) .866 D+R + 1.072 (25) 4.072 (33–3.48) .374 .374 D+R + 1.072 (26) 4.072 (33–3.48) .463 .463 .463 D+R + 1.072 (33–3.48) .148 <td< td=""><td>Heart</td><td>9 (11)</td><td>18 (11)</td><td></td><td></td></td<>	Heart	9 (11)	18 (11)		
Kinney 36 (42) 72 (43) Duer 9 (11) 17 (10) Parcoas 1 (1) 2 (1) Median [10R] number of transplants 1 [1-1] <	Lung	30 (35)	60 (36)		
Lvar 9 (11) 17 (10) Pancress 1 (1) 2 (1) Median [IGR] unber of transplants 1 [1-1] 1 [1-1] 1 7 (7 43 - 75) 181 Median [IGR] unber of transplants 1 [1-1] 1 [1-1] 1 7 (7 43 - 75) 181 Median [IGR] unber of transplant therapy 1 26 (5) 3 (8 12 - 50) 1 20 (3 0 - 1.05) 1.47 Median [IGR] unber of transplant therapy 1 26 (5) 2 0.16 (1 12) 1 3 (1 5 - 3.17) 433 Peattransplant mechanical ventilation 3 2779 (1) 0 27 (1 2 1 3 - 10 (1 6 3 - 3.17) 433 DevR = 1 2772 (2 0) 2 0.471 (1 2) 1 22 (4 3 - 2.17) 486 D-rR + 1 2772 (2 1) 2 1 0 (1 3 - 4.38) 314 32 (3 - 3.18) 344 D-rR + 1 2772 (2 1) 2 4 (1 4) 1 7 (8 (3 - 4.38) 1.43 344 Median [IGR] wirel to CMV disesse 1 81 (2 - 2.39) 1 24 (2 - 3.2) 1.00 (4 9 - 4.13) 434 Median [IGR] wirel to CMV disesse in day 1 0 (2 - 3.2) 4 4 4 3 7 (1 3 (3 - 5.1) 3 (1 3 - 5 - 2.1)	Kidney	36 (42)	72 (43)		
Pancress 1 (1) 2 (1) Median IICBI page at transplant in years 56 (44–63) 52 (36–61) 1.0.0 (10–1.06) .0.09 Median IICBI number of transplant ICU stay in days 3 (0–9) 2 (0–6) 1.0.0 (10–1.06) .0.77 Median IICBI number of transplant ICU stay in days 3 (0–9) 2 (0–6) 1.0.0 (1.00–1.06) .0.77 Post-transplant transleptint ICU stay in days 3 (0–9) 2 (0–6) 1.0.0 (1.00–1.06) .0.77 Post-transplant transleptint ICU stay in days 3 (0–9) 2 (0–6) 1.0.0 (1.0–1.06) .0.77 Post-transplant transleptint ICU stay in days 3 (0–9) 2 (0–6) 1.0.2 (1.4–2.82) .0.81 DerK+ 2 (272 (31) 3 (0/127) 1.0.9 (1.42–2.84) .0.83 .0.9 .0.81 .0.9 .0.72 (32) .72 (35–3.09) .0.91 .0.91 (40–2.48) .0.86 .0.71 (32) .72 (35–3.48) .1.37 .0.91 (40–2.48) .0.91 (40–2.48) .0.91 (40–2.48) .0.91 (40–2.48) .0.91 (40–2.48) .0.91 (40–2.48) .0.91 (40–2.48) .0.91 (40–2.48) .0.91 (40–2.48) .0.91 (40–2.48) .0.91 (40–2.	Liver	9 (11)	17 (10)		
Median (ICR) number of transplants 11-11 1.71/1-78-7.79 1.03 (1.01-1.06) 009 Median (ICR) number of transplants 11-11 1.11-11 1.71/1-78-7.79 1.81 Median (ICR) number of transplant ICU stay in days 3 (0-9) 2 (0-6) 1.02 (199-1.06) 1.07 Post-transplant mechanical wantilation 32/79 (41) 62/76 (40) 1.12 (44-2.82) 813 Post-R 22/72 (31) 33/127 (31) 1.07 (189-2.17) 486 D-/R 22/72 (31) 33/127 (31) 1.07 (189-2.17) 486 D-/R 22/72 (31) 33/127 (31) 1.07 (189-2.17) 486 D-/R 1977 (26) 40/127 (32) .72 (35-1.49) 374 Post-transplant to V/ disease 18 (2) 2 4 (14) 1.70 (199-3.20) 1.00 (199-1.00) Post-transplant to CMV disease in days 106 (29-230) 11 42-277 100 (199-1.00) 499 Median (ICR) time to CMV disease in days 106 (29-230) 11 42-277 100 (199-1.00) 96 Consorbidies ⁴ 2 101 1.51 (15.2) 1.52 1.52	Pancreas	1 (1)	2 (1)		
Median (IDR) number of transplants 1 [1-1]	Median [IQR] age at transplant in years	58 [44–63]	52 [39–61]	1.03 (1.01–1.06)	.009
Median (10R) legner years 45.8 [28–66] 38 [23–50] 1.02 (39-1.05) 1.147 Median (10R) legner years 3091 2.(-6-6) 1.03 (1.00-1.05) 007 Post-transplant renal replacement therapy 1282 (15) 2.0/161 (12) 1.37 (159-3.17) .463 Post-transplant renal replacement therapy 1282 (15) 2.0/16 (12) 1.37 (159-3.17) .463 V/V serological status	Median [IQR] number of transplants	1 [1–1]	1 [1–1]	1.71 (.78–3.75)	.181
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Median [IQR] donor age in years	43.5 [26–56]	38 [23–50]	1.02 (.99–1.05)	.147
Post-transplent renal replacement therapy 12/82 (15) 20/161 (12) 1.37 (159-317) 4.463 Post-transplent mechanical ventilation 32/79 (41) 62/156 (40) 1.21 (44-2.82) 813 D-//R + 12 (44-2.82) 813 D-//R + 22/72 (31) 39/127 (31) 1.09 (149-2.45) 8.36 D-//R + 14/72 (19) 22/127 (17) 1.32 (157-3.09) 5.18 D+//R - 19/72 (26) 40/127 (32) 7.2 (35-1.48) 3.74 Post-transplant CMV disease 18 (2) 24 (14) 1.70 (183-3.45) 1.43 Median (IOR) transload in copies/ml 1480 (780-29*000) 24*327 (1603-90*000) 1.00 (199-1.00) 4.09 Median (IOR) transload in copies/ml 1480 (780-29*000) 24*327 (1603-90*000) 1.00 (199-1.00) 4.09 Median (IOR) transload in copies/ml 1480 (780-29*000) 24*327 (1603-90*000) 1.00 (199-1.00) 4.09 Median (IOR) transload in copies/ml 1480 (780-29*000) 24*327 (1603-90*000) 1.00 (199-1.00) 4.09 Median (IOR) transload in copies/ml 13 (15) 2.1 (12) 1.36 (59-3.22) 4.67 Diabetes mellus 27 (22) 55 (33) 496 (53-1.72) 881 Hypertansion 37 (44) 80 (47) 82 (44-1.52) 532 Chronic tidney disease 36 (42) 58 (34) 1.64 (185-3.15) .139 Congestive heart failure 13 (15) 15 (19) 2.62 (139-7.33) 6.07 Cardiac arrhythmia 10 (12) 13 (16) (167-3.86) 2.49 Gastroseophageal disease 15 (16) 25 (13) 2.19 (15-8.16) 2.49 Gastroseophageal disease 15 (16) 25 (13) 2.19 (15-8.28) 2.49 Gastroseophageal disease 15 (16) 25 (15) 1.31 (5-8.13) .505 End-stage Inter disease 15 (16) 2.5 (13) 4.59 (15-4.41) 107 Pulmonary circulation disorders 5 (56) 5.13 4.59 (15-4.41) 107 Pulmonary circulation disorders 10 (12) 7 (14) 3.12 (1.12-8.66) 2.029 Autommune disease 15 (16) 2.5 (15) 1.31 (6-2.81) .505 End-stage Inter disease 15 (16) 2.5 (15) 1.33 (15-8.13) .505 End-stage Inter disease 15 (16) 2.5 (15) 2.5 (15-6.61) .604 Risk tactors within 90 days of index date Concomitant infections 9 (10) 1.6 (12-7.956 Use of PPL or H2-RAs 54 (64) 1.17 (69) 1.5 (3-4-6.7) .906 Use of PPLs or H2-RAs 54 (64) 1.17 (7) 3.35 (15-8.65) 2.28 Systemic corticosteroids 72 (65) 1.26 (75) 3.11 (1.14-8.49) 0.27 Average predinsone does in mg, median [IOR] ⁴ 10 [5-15] 5.	Median [IQR] length of post-transplant ICU stay in days	3 [0–9]	2 (0–6)	1.03 (1.00–1.05)	.077
Post-transplant mechanical ventilation $32/9$ (41) $62/160$ (0) 1.12 (44–2.82) .813 D-/R = 127/2 (24) 26/127 (21) 1.90 (48–2.45) .836 D-/R + 227/2 (31) 39/127 (31) 1.07 (53–2.17) .866 D-/R = 19/72 (26) 40/127 (32) .72 (35–4.89) .374 D-/R = 19/72 (26) 40/127 (32) .72 (35–4.89) .374 D-/R = 19/72 (26) 40/127 (32) .72 (35–4.89) .374 Dest-transplant CMV disease in days 106 [29–239] 131 (42–227) 1.00 (399–1.00.1) .409 Median [IQR] time to CMV disease in days 106 [29–239] 131 (42–227) 1.00 (399–1.00.1) .998 Comorbidities ⁴ Dest-transplant CMV disease in days 106 [29–239] 131 (42–227) 1.00 (399–1.00.1) .998 Comorbidities ⁴ Dest-transplant failure 1 .201 .138 (59–3.22) .462 Diabetes mellitus 27 (32) .55 (33) .96 (53–1.72) .881 Diabetes mellitus 27 (32) .55 (33) .96 (53–1.72) .881 Diabetes mellitus 27 (32) .55 (33) .96 (53–1.72) .881 Comorbidities ⁴ Diabetes mellitus 20 (732) .55 (33) .96 (53–1.72) .881 Diabetes mellitus 10 (12) .13 (80 .161 (67–3.85) .284 Chronic kidney disease 36 (42) .58 (34) .164 (85–3.15) .139 Congestive heart failure 13 (15) .15 (9) .2 (28 (33–7.33) .067 Cardiac arhythmia 10 (12) .13 (8) .161 (67–3.85) .284 Chronic lung disorders 5 (6) .5 (3) .2.19 (58–3.6) .249 Gastroesophageal disease 15 (18) .25 (15) .13 (6–2.81) .055 End stage liver disease .5 (6) .5 (3) .2.19 (58–3.6) .249 Gastroesophageal disease .15 (18) .25 (15) .13 (6–2.81) .055 End stage liver disease .15 (18) .25 (15) .13 (6–2.81) .056 End stage liver disease .15 (18) .25 (15) .13 (6–2.81) .056 End stage liver disease .15 (18) .25 (15) .3 (16–2.81) .056 End stage liver disease .15 (18) .25 (15) .3 (16–2.81) .056 End stage liver disease .15 (18) .25 (15) .3 (16–2.81) .056 End stage liver disease .15 (18) .25 (15) .3 (16–2.81) .056 End stage liver disease .15 (18) .25 (15) .3 (11 (1.4–4.57) .566 Use of PPs or H2-RAS .5 (6) .13 (6) .3 (11 (1.4–4.67) .566 Use of PPs or H2-RAS .5 (6) .13 (6) .3 (10 (4–2.13) .288 Immunosuppression at the time of diagnosis* Carcomitant infections at the time of diagnosi	Post-transplant renal replacement therapy	12/82 (15)	20/161 (12)	1.37 (.59–3.17)	.463
CMV servlogical status D-R = 17/2 (24) $26/127$ (21) 1.00 (48–2.45) $836D-R + 22/72$ (31) $38/127$ (31 1.07 (53–2.17) $856D-R + 14/72$ (19) $22/127$ (17) 1.22 (57–3.09) $518D-R - 19/72$ (26) $40/127$ (32) $.72$ (35–1.48) $374Post-transplant CMV disease 18(2) 24(14) 1.70 (83–3.48) 143Median [IQR] trial load in copies/ml 1486 [780–29°000] 24^437 (603–90°500] 1.00 (99–1.0) 4.09Median [IQR] trine to CMV disease in days 166 [29–239] 131 (42–227) 100 (199–1.00) 1.998Comobilities4Obesity (BMI §30 kg/m2) 13 (15) 21 (12) 1.38 (59–3.22) 462Obesity (BMI §30 kg/m2) 37 (44) 80 (47) 82 (44–1.52) 328Chronic kinkey disease 36 (42) 58 (34) 1.64 (45–3.15) 139Congestive heart failure 13 (15) 15 (9) 2.62 (93–7.33) .067Cardiac arrhythma 10 (12) 13 (8) 1.61 (67–3.85) .284Chronic kinkey disease 5 (6) 5 (3) 2.19 (58–8.36) .249Gastroscophageal disease 15 (18) 25 (15) 1.3 (16–2.81) .072Pulmonary circulation disorders 5 (6) 5 (3) 2.19 (58–8.36) .249Gastroscophageal disease 5 (0) 5 (3) 2.19 (58–8.36) .249Gastroscophageal disease 15 (18) 25 (15) 1.3 (16–2.81) .056Ref k factors within 90 days of index dateConcomitant infections 31 (66) 9 (5) 22.85 (5.15–108.65) .209Autoimmune disease 5 (60) 5 (3) 4.24 (12–2.13) .066KeX factors within 90 days of index dateConcomitant infections 31 (66) 9 (5) 22.85 (5.15–108.65) .<001Haspital admission 27 (22) 31 (18) 2.84 (134–6.01) .066CU admission 27 (23) 31 (18) 2.84 (134–6.01) .066CU admission 27 (26) 126 (75) 3.111 (14–8.40) .907Mycophenolate 56 (69) 118 (70) .36 (48–1.9) .907Mycophenolate 70 (62) 141 (83) .94 (42–2.13) .890Mycophenolate 70 (62) 141 (83) .94 (42–2.13) .890Mycophenolate 70 (62) 141 (83) .94 (42–2.13) .890Mycophenolate 70 (62) 141 (78–685,5) 228Systemic corticosteroids 72 (65) 126 (75) .3111 (14–8.45) .027Avara$	Post-transplant mechanical ventilation	32/79 (41)	62/156 (40)	1.12 (.44–2.82)	.813
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	CMV serological status				
	D-/R -	17/72 (24)	26/127 (21)	1.09 (.48–2.45)	.836
	D+/R +	22/72 (31)	39/127 (31	1.07 (.53–2.17)	.856
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	D-/R +	14/72 (19)	22/127 (17)	1.32 (.57–3.09)	.518
Post-transplant CMV disease 18 (2) 24 (4) 1.70 (43-3.46) 1.143 Median [ICR] time to CMV disease in days 106 [29-239] 131 [42-227] 1.00 (99-1.001) .998 Comonicities ³	D+/R -	19/72 (26)	40/127 (32)	.72 (.35–1.48)	.374
Median [ICH] virial load in copies/mit 1488 [780-29*00] $24*39$ [103-300*500] 1.00 (199-1.0) .409 Median [ICH] time to CMV disease in days 106 [29-239] 13 [142-227] 1.00 (199-1.0001) .998 Comorbidities ⁴	Post-transplant CMV disease	18 (2)	24 (14)	1.70 (.83–3.48)	.143
Median (ICR) time to CMV disease in days 106 (29–239) 131 (42–227) 1.00 (399–1.0001) .998 Comorbidities ⁴ Obesity (BMI 2:30 Kg/m ²) 13 (15) 21 (12) 1.38 (59–3.22) .462 Diabetes mellitus 27 (32) 55 (33) .96 (53–1.72) .881 Hypertension 37 (44) 80 (47) .82 (.44–1.52) .532 Chronic kidney disease 36 (42) 58 (34) 1.46 (.85–3.15) .139 Congestive heart failure 13 (15) 15 (9) 2.62 (.93–7.33) .067 Cardiac arrhythmia 10 (12) 13 (8) 1.61 (.67–3.85) .284 Chronic king disorders 5 (6) 5 (3) 2.19 (.58–3.6) .249 Gastroesophageal disease 15 (18) 25 (15) 1.3 (.6–2.81) .505 End-stage liver disease 5 (6) 5 (3) 4.59 (.5–4.24) .179 Qastroesophageal disease 12 (14) 12 (7) 2.5 (.95–6.61) .064 Ris factors within 90 days of index date 2 2 31 (18) 2.84 (1.34–6.01) .006	Median [IQR] viral load in copies/ml	1486 [780–29°000]	24°437 [6033–90°500]	1.00 (.99–1.0)	.409
Combinities ²⁴ Obesity (BMI ≥30 Kg/m ²) 13 (15) 21 (12) 1.38 (59-3.22) .462 Diabetes melitus 27 (32) 55 (33) .96 (53-1.72) .881 Hypertension 37 (44) 80 (47) .82 (44-1.52) .532 Chronic kidney disease .36 (42) .58 (34) 1.64 (85-3.15) .139 Congestive heart failure 13 (15) 15 (9) .26 (2(33-7.33) .067 Cardiac arrhythmia 10 (12) 13 (8) 1.61 (67-3.85) .284 Chronic lung disorders 5 (6) 5 (3) 2.19 (58-8.36) .249 Gastrosephageal disease 15 (18) .25 (15) 1.3 (6-2.81) .505 End-stage liver disease 10 (12) 7 (4) .312 (1.12-8.65) .029 Autoimmune disease 12 (14) 12 (7) .2.5 (56-6.1) .064 Risk factors within 90 days of index date	Median [IQR] time to CMV disease in days	106 [29–239]	131 [42–227]	1.00 (.999- 1.0001)	.998
Observe (BMI ≥30 Kg/m²) 13 (15) 21 (12) 1.38 (58-3.22) 4.62 Diabetes mellitus 27 (32) 55 (33) .96 (5.3-1.72) .881 Hypertension 37 (44) 80 (47) 82 (44-1.52) .532 Chronic kidney disease 36 (42) 58 (34) 1.64 (85-3.15) .139 Congestive heart failure 13 (15) 15 (9) 2.62 (39-7.33) .067 Cardiac arhythmia 10 (12) 13 (8) 1.61 (67-3.85) .284 Chronic lung disorders 16 (19) 20 (12) 1.91 (87-4.18) .107 Pulmonary circulation disorders 5 (6) 5 (3) 2.19 (58-8.36) .249 Gatroesophageal disease 15 (18) 2.51 (15) 1.3 (6-2.81) .505 End-stage liver disease 16 (16) 3 (12 (1.12-8.65) .029 Autoimmure disease .022 Autoimmure disease .029 Autoimmure disease .029 Autoimmure disease .001 .064 .001 .064 .001 .064 .001 .064 .001 .006 .001	Comorbidities"		// ->		
Diabetes mellitus27 (32)55 (33)	Obesity (BMI ≥30 Kg/m²)	13 (15)	21 (12)	1.38 (.59–3.22)	.462
Hypertension $3/441$ $80(47)$ $80(47)$ $82(44-1.52)$ 5.32 Chronic kidney disease $36(42)$ $58(34)$ $1.64(85-3.15)$ 1.39 Congestive heart failure $13(15)$ $15(9)$ $2.62(33-7.33)$ 0.67 Cardiac arrhythmia $10(12)$ $13(8)$ $1.61(.67-3.85)$ 2.84 Chronic lung disorders $16(19)$ $20(12)$ $1.91(87-4.18)$ 1.07 Pulmonary circulation disorders $5(6)$ $5(3)$ $2.19(.58-8.36)$ 2.49 Gastroscophageal disease $15(18)$ $25(15)$ $1.3(6-2.81)$ 505 End-stage liver disease $5(6)$ $5(3)$ $4.59(.5-42.4)$ 1.79 Cancer $10(12)$ $7(4)$ $3.12(1.12-8.65)$ 0.29 Autoimmune disease $12(14)$ $12(7)$ $2.5(95-6.61)$ 0.64 Risk factors within 90 days of index date $U(12)$ $7(4)$ $3.12(1.12-8.65)$ 0.29 Concomitant infections $31(36)$ $9(5)$ $25.85(6.15-108.65)$ <001	Diabetes mellitus	27 (32)	55 (33)	.96 (.53–1.72)	.881
Chronic kidney disease 36 (42) 58 (34) 1.64 (35–3,15) 1.139 Congestive heart failure 13 (15) 15 (9) 2.62 (39–7,33) 067 Cardiac arrhythmia 10 (12) 13 (8) 1.61 (.67–3,85) .284 Chronic lung disorders 5 (6) 5 (3) 2.19 (.58–8.36) .249 Gastroesophageal disease 15 (18) 25 (15) 1.3 (.6–2.81) .605 End-stage liver disease 5 (6) 5 (3) 4.59 (.5–42.4) .179 Cancer 10 (12) 7 (4) 3.12 (1.12–8.65) .029 Autoimmune disease 12 (14) 12 (7) 2.5 (.95–6.61) .064 Risk factors within 90 days of index date .0029 .410 .027 .25 (.95–6.61) .064 Indeprision 27 (32) 31 (18) 2.84 (1.34–6.01) .006 .000 .25 (.95–6.61) .006 .000 .400 .000 .000 .000 .000 .000 .000 .000 .000 .000 .0000 .000 .0000	Hypertension	37 (44)	80 (47)	.82 (.44–1.52)	.532
Congestive heart tailure 13 (15) 15 (9) 2.62 (93-7.33) .067 Cardiac arrhythmia 10 (12) 13 (8) 1.61 (67-3.85) .284 Chronic lung disorders 16 (19) 20 (12) 1.91 (87-4.18) 107 Pulmonary circulation disorders 5 (6) 5 (3) 2.19 (58-8.36) .249 Gastroesophageal disease 15 (18) 25 (15) 1.3 (6-2.81) .505 End-stage liver disease 5 (6) 5 (3) 4.59 (5-42.4) .179 Cancer 10 (12) 7 (4) 3.12 (1.12-8.65) .029 Autoimmune disease 12 (14) 12 (7) 2.5 (.95-6.61) .064 Risk factors within 90 days of index date .029 .41 (134-6.01) .006 ICU admission 27 (32) 31 (18) 2.84 (1.34-6.7) .596 .596 .501 .616 .51.34-6.7) .596 Use of PPIs or H2-RAs 54 (64) 117 (69) .71 (.38-1.33) .288 .284 .346-7) .596 Use of PPIs or H2-RAs 59 (69) <td>Chronic kidney disease</td> <td>36 (42)</td> <td>58 (34)</td> <td>1.64 (.85–3.15)</td> <td>.139</td>	Chronic kidney disease	36 (42)	58 (34)	1.64 (.85–3.15)	.139
Cardiac arrivitimia 10 (12) 13 (8) 1.61 (67-3.85) .284 Chronic lung disorders 16 (19) 20 (12) 1.91 (87-4.18) 1.07 Pulmonary circulation disorders 5 (6) 5 (3) 2.19 (58-8.36) .249 Gastroesophageal disease 15 (18) 25 (15) 1.3 (.6-2.81) .505 End-stage liver disease 5 (6) 5 (3) 4.59 (.5-42.4) .179 Cancer 10 (12) 7 (A) 3.12 (1.12-8.65) .029 Autoimmune disease 12 (14) 12 (7) 2.5 (.95-6.61) .064 Risk factors within 90 days of index date 2 2 31 (18) 2.84 (1.34-6.01) .006 Concomitant infections 9 (11) 16 (9) 1.5 (34-6.7) .596 Use of PPIs or H2-RAs 54 (64) 117 (69) .71 (.38-1.33) .288 Immunosuppression at the time of diagnosis ^e 2 2 .66-5.85) .228 Calcineurin inhibitor 70 (82) 141 (83) .94 (.42-2.13) .890 Mycophenolate 59 (69)	Congestive heart failure	13 (15)	15 (9)	2.62 (.93–7.33)	.067
Chronic fung disorders16 (19) $Z0 (12)$ 1.91 (37-4, 18)1.07Pulmonary circulation disorders5 (6)5 (3)2.19 (.58-8.36).249Gastroesophageal disease15 (18)25 (15)1.3 (6-2.81).505End-stage liver disease5 (6)5 (3)4.59 (5-42.4).179Cancer10 (12)7 (4)3.12 (1.12-8.65).029Autoimmune disease12 (14)12 (7)2.5 (.95-6.61).064Risk factors within 90 days of index date.Concomitant infections31 (36)9 (5)25.85 (6.15-108.65)<.001	Cardiac arrhythmia	10 (12)	13 (8)	1.61 (.67–3.85)	.284
Pulmonary circulation disorders 5 (6) 5 (3) 2.19 (.58-8.36) 2.249 Gastroesophageal disease 15 (18) 25 (15) 1.3 (6-2.81) .505 End-stage liver disease 5 (6) 5 (3) 4.59 (.5-42.4) .179 Cancer 10 (12) 7 (4) 3.12 (1.12-8.65) .029 Autoimmune disease 12 (14) 12 (7) 2.5 (.95-6.61) .064 Risk factors within 90 days of index date .029 Concomitant infections 31 (36) 9 (5) 25.85 (6.15-108.65) <.001	Chronic lung disorders	16 (19)	20 (12)	1.91 (.87–4.18)	.107
Gastroesophageal disease 15 (18) 25 (15) 1.3 (6-2.81) 5.005 End-stage liver disease 5 (6) 5 (3) 4.59 (5-42.4) .179 Cancer 10 (12) 7 (4) 3.12 (1.12-8.65) .029 Autoimmune disease 12 (14) 12 (7) 2.5 (.95-6.61) .064 Risk factors within 90 days of index date 27 (32) 31 (18) 2.84 (1.34-6.01) .006 Hospital admission 27 (32) 31 (18) 2.84 (1.34-6.01) .006 ICU admission 9 (11) 16 (9) 1.5 (.34-6.7) .596 Use of PPIs or H2-RAs 54 (64) 117 (69) .71 (.38-1.33) .288 Immunosuppression at the time of diagnosis ^e	Pulmonary circulation disorders	5 (6)	5 (3)	2.19 (.58-8.36)	.249
End-stage liver disease 5 (6) 5 (3) 4.59 (5-42.4) 1.179 Cancer 10 (12) 7 (4) 3.12 (1.12-8.65) 0.029 Autoimmune disease 12 (14) 12 (7) 2.5 (35-6.61) 0.64 Risk factors within 90 days of index date 2 2.5 (35-6.61) 0.64 Concomitant infections 31 (36) 9 (5) 25.85 (6.15-108.65) <.001 Hospital admission 27 (32) 31 (18) 2.84 (1.34-6.01) 0.06 ICU admission 9 (11) 16 (9) 1.5 (.34-6.7) .596 Use of PPIs or H2-RAs 54 (64) 117 (69) .71 (.38-1.33) .288 Immunosuppression at the time of diagnosis ^e	Gastroesophageal disease	15 (18)	25 (15)	1.3 (.6–2.81)	.505
Cancer 10 (12) 7 (4) 3.12 (1.12–8.65) .029 Autoimmune disease 12 (14) 12 (7) 2.5 (.95–6.1) .064 Risk factors within 90 days of index date 2 2 14 12 (7) 2.5 (.95–6.1) .064 Risk factors within 90 days of index date 31 (36) 9 (5) 25.85 (6.15–108.65) <.001	End-stage liver disease	5 (6)	5 (3)	4.59 (.5-42.4)	.179
Autommune disease 12 (1) 12 (1) 12 (1) 12 (1) 12 (1) 10 (10 (10 (10 (10 (10 (10 (10 (10 (10 (10 (12)	/ (4)	3.12 (1.12-8.65)	.029
Nisk ractors within 90 days of index date Concomitant infections 31 (36) 9 (5) 25.85 (6.15–108.65) <.001	Autoimmune disease	12 (14)	12 (7)	2.5 (.95-6.61)	.064
Concomitant infections 31 (36) 9 (5) 25.85 (6.15–108.65) <.001 Hospital admission 27 (32) 31 (18) 2.84 (1.34–6.01) .006 ICU admission 9 (11) 16 (9) 1.5 (.34–6.7) .596 Use of PPIs or H2-RAs 54 (64) 117 (69) .71 (.38–1.33) .288 Immunosuppression at the time of diagnosis ^e .99 (69) 141 (83) .94 (.42–2.13) .890 Mycophenolate 59 (69) 118 (70) .96 (.48–1.9) .907 mTor inhibitor 10 (12) 13 (8) 1.96 (.66–5.85) .228 Systemic corticosteroids 72 (85) 126 (75) 3.11 (1.14–8.49) .027 Average prednisone dose in mg, median [IQR] ^f 10 [5–15] 5 [5–15] 1.01 (.99–1.03) .244 Lymphocyte-specific antibodies ⁹ 8 (9) 11 (7) 3.35 (.59–18.88) .171 Organ rejection prior to the index date ^h 16 (19) 26 (16) 1.39 (.63–3.07) .416 Median [IQR] days from rejection to index date 214 (78.5–685.5) 985.5 (262–3215)	Risk factors within 90 days of index date	01 (00)	0 (5)		. 001
Hospital admission 27 (32) 31 (18) 2.84 (1.34–6.01) .006 ICU admission 9 (11) 16 (9) 1.5 (.34–6.7) .596 Use of PPIs or H2-RAs 54 (64) 117 (69) .71 (.38–1.33) .288 Immunosuppression at the time of diagnosis ^e 2 141 (83) .94 (.42–2.13) .890 Mycophenolate 59 (69) 118 (70) .96 (.48–1.9) .907 mTor inhibitor 10 (12) 13 (8) 1.96 (.66–5.85) .228 Systemic corticosteroids 72 (85) 126 (75) 3.11 (1.14–8.49) .027 Average prednisone dose in mg, median [IQR] ^f 10 [5–15] 5 [5–15] 1.01 (.99–1.03) .244 Lymphocyte-specific antibodies ⁹ 8 (9) 11 (7) 3.35 (.59–18.88) .171 Organ rejection prior to the index date ^h 16 (19) 26 (16) 1.39 (.63–3.07) .416 Median [IQR] days from rejection to index date 214 (78.5–685.5) 985.5 (262–3215) 1.0 (.99–1) .47 Concomitant infections at the time of diagnosis 31 (13) 2 (1) 10.85 (2.42–48.71) .002 Bacterial 11 (13) 2 (1)		31 (36)	9 (5)	25.85 (6.15-108.65)	<.001
LCO admission 9 (11) 16 (9) 1.5 (.34–6.7) .596 Use of PPIs or H2-RAs 54 (64) 117 (69) .71 (.38–1.33) .288 Immunosuppression at the time of diagnosis ^e 2 141 (83) .94 (.42–2.13) .890 Mycophenolate 59 (69) 118 (70) .96 (.48–1.9) .907 mTor inhibitor 10 (12) 13 (8) 1.96 (.66–5.85) .228 Systemic corticosteroids 72 (85) 126 (75) 3.11 (1.14–8.49) .027 Average prednisone dose in mg, median [IQR] ^f 10 [5–15] 5 [5–15] 1.01 (.99–1.03) .244 Lymphocyte-specific antibodies ^a 8 (9) 11 (7) 3.35 (.59–18.88) .171 Organ rejection prior to the index date ^h 16 (19) 26 (16) 1.39 (.63–3.07) .416 Median [IQR] days from rejection to index date 214 (78.5–685.5) 985.5 (262–3215) 1.0 (.99–1) .47 Concomitant infections at the time of diagnosis 31 (13) 2 (1) 10.85 (2.42–48.71) .002 Europal 13 (15) 5 (3) 20.54 (2.64–159.75) .004		27 (32)	31 (18)	2.84 (1.34-0.01)	.000
Ose of PPIs of H2-HAS 54 (64) 117 (69) .77 (.38–1.33) .268 Immunosuppression at the time of diagnosis ^e Calcineurin inhibitor 70 (82) 141 (83) .94 (.42–2.13) .890 Mycophenolate 59 (69) 118 (70) .96 (.48–1.9) .907 mTor inhibitor 10 (12) 13 (8) 1.96 (.66–5.85) .228 Systemic corticosteroids 72 (85) 126 (75) 3.11 (1.14–8.49) .027 Average prednisone dose in mg, median [IQR] ^f 10 [5–15] 5 [5–15] 1.01 (.99–1.03) .244 Lymphocyte-specific antibodies ⁹ 8 (9) 11 (7) 3.35 (.59–18.88) .171 Organ rejection prior to the index date ^h 16 (19) 26 (16) 1.39 (.63–3.07) .416 Median [IQR] days from rejection to index date 214 (78.5–685.5) 985.5 (262–3215) 1.0 (.99–1) .47 Concomitant infections at the time of diagnosis Bacterial 11 (13) 2 (1) 10.85 (2.42–48.71) .002 Fungal 13 (15) 5 (3) 20.54 (2.64–159.75) .004 <td></td> <td>9(11)</td> <td>10 (9)</td> <td>71 (20, 1, 22)</td> <td>.090</td>		9(11)	10 (9)	71 (20, 1, 22)	.090
Calcineurin inhibitor 70 (82) 141 (83) .94 (.42–2.13) .890 Mycophenolate 59 (69) 118 (70) .96 (.48–1.9) .907 mTor inhibitor 10 (12) 13 (8) 1.96 (.66–5.85) .228 Systemic corticosteroids 72 (85) 126 (75) 3.11 (1.14–8.49) .027 Average prednisone dose in mg, median [IQR] ^f 10 [5–15] 5 [5–15] 1.01 (.99–1.03) .244 Lymphocyte-specific antibodies ⁹ 8 (9) 11 (7) 3.35 (.59–18.88) .171 Organ rejection prior to the index date ^h 16 (19) 26 (16) 1.39 (.63–3.07) .416 Median [IQR] days from rejection to index date 214 (78.5–685.5) 985.5 (262–3215) 1.0 (.99–1) .47 Concomitant infections at the time of diagnosis 5 (3) 20 54 (2 64–159 75) .004	Use of PPIs of HZ-RAS	54 (64)	117 (09)	./1 (.38-1.33)	.288
Calchredin minutor 70 (82) 141 (83)	Calainouvin inhibitor	70 (92)	1 / 1 / (93)	04/42 2 12)	000
Import inhibitor 10 (12) 13 (8) 1.96 (.46–1.9) .907 mTor inhibitor 10 (12) 13 (8) 1.96 (.66–5.85) .228 Systemic corticosteroids 72 (85) 126 (75) 3.11 (1.14–8.49) .027 Average prednisone dose in mg, median [IQR] ^f 10 [5–15] 5 [5–15] 1.01 (.99–1.03) .244 Lymphocyte-specific antibodies ⁹ 8 (9) 11 (7) 3.35 (.59–18.88) .171 Organ rejection prior to the index date ^h 16 (19) 26 (16) 1.39 (.63–3.07) .416 Median [IQR] days from rejection to index date 214 (78.5–685.5) 985.5 (262–3215) 1.0 (.99–1) .47 Concomitant infections at the time of diagnosis 11 (13) 2 (1) 10.85 (2.42–48.71) .002 Fungal 13 (15) 5 (3) 20.54 (2.64–159.75) .004		70 (62)	141 (03)	.94 (.42-2.13)	.090
Information 10 (12) 13 (b) 1.96 (.00-5.85) .228 Systemic corticosteroids 72 (85) 126 (75) 3.11 (1.14-8.49) .027 Average prednisone dose in mg, median [IQR] ^f 10 [5-15] 5 [5-15] 1.01 (.99-1.03) .244 Lymphocyte-specific antibodies ⁹ 8 (9) 11 (7) 3.35 (.59-18.88) .171 Organ rejection prior to the index date ^h 16 (19) 26 (16) 1.39 (.63-3.07) .416 Median [IQR] days from rejection to index date 214 (78.5-685.5) 985.5 (262-3215) 1.0 (.99-1) .47 Concomitant infections at the time of diagnosis 11 (13) 2 (1) 10.85 (2.42-48.71) .002 Fungal 13 (15) 5 (3) 20 54 (2 64-159 75) .004		10 (12)	110 (70)	1.06 (66 5.95)	.907
Average prednisone dose in mg, median [IQR] ^f 10 [5–15] 5 [5–15] 1.01 (.99–1.03) .244 Lymphocyte-specific antibodies ^q 8 (9) 11 (7) 3.35 (.59–18.88) .171 Organ rejection prior to the index date ^h 16 (19) 26 (16) 1.39 (.63–3.07) .416 Median [IQR] days from rejection to index date 214 (78.5–685.5) 985.5 (262–3215) 1.0 (.99–1) .47 Concomitant infections at the time of diagnosis 11 (13) 2 (1) 10.85 (2.42–48.71) .002 Fungal 13 (15) 5 (3) 20.54 (2.64–159.75) 004	Svetemie sertiesstoreide	10 (12)	13 (8)	1.90 (.00-0.80)	.228
Average predictione dose in Fig. Ineutant (id.f) 10 (2-15) 5 (2-15) 1.01 (.32-1.03) 2.244 Lymphocyte-specific antibodies ^a 8 (9) 11 (7) 3.35 (.59-18.88) .171 Organ rejection prior to the index date ^h 16 (19) 26 (16) 1.39 (.63-3.07) .416 Median [IQR] days from rejection to index date 214 (78.5–685.5) 985.5 (262–3215) 1.0 (.99–1) .47 Concomitant infections at the time of diagnosis Bacterial 11 (13) 2 (1) 10.85 (2.42–48.71) .002 Fungal 13 (15) 5 (3) 20 54 (2 64–159 75) .004	Average produisant dose in ma modian [IOP] ^f	10 [5, 15]	5 [5 15]	1 01 (00 1 02)	.027
Eyrinplicy (sespectine antibodies) 6 (s) 11 (1) 5.33 (.39–18.88) .171 Organ rejection prior to the index date ^h 16 (19) 26 (16) 1.39 (.63–3.07) .416 Median [IQR] days from rejection to index date 214 (78.5–685.5) 985.5 (262–3215) 1.0 (.99–1) .47 Concomitant infections at the time of diagnosis 31 (13) 2 (1) 10.85 (2.42–48.71) .002 Fungal 13 (15) 5 (3) 20 54 (2 64–159 75) .004	Average preunsone dose in mg, median [IQA]	0 [0-10]	11 /7	3 35 (50, 10,00)	.244
Organ rejection plot to the index date 10 (13) 20 (10) 1.39 (.03–3.07) .416 Median [IQR] days from rejection to index date 214 (78.5–685.5) 985.5 (262–3215) 1.0 (.99–1) .47 Concomitant infections at the time of diagnosis 3 11 (13) 2 (1) 10.85 (2.42–48.71) .002 Eungal 13 (15) 5 (3) 20 54 (2 64–159 75) .004	Organ rejection prior to the index data ^h	16 (10)	26 (16)	1 39 (62 - 2 07)	.171
We lian (Car) days non rejection to index date 214 (76.5-065.5) 985.5 (202-52.15) 1.0 (.39-1) .47 Concomitant infections at the time of diagnosis 11 (13) 2 (1) 10.85 (2.42-48.71) .002 Europal 13 (15) 5 (3) 20 54 (2 64-159 75) .004	Median [IOR] days from rejection to index date	214 (78 5 605 5)	085 5 (262 2215)	1.0.00 (.00 1)	.410
Bacterial 11 (13) 2 (1) 10.85 (2.42–48.71) .002 Fungal 13 (15) 5 (3) 20 54 (2 64–159 75) 004	Concomitant infections at the time of discussio	214 (70.0-000.0)	909.0 (202-3210)	1.0 (.33-1)	.47
Europai 11 (15) 2 (1) 10.05 (2.42=46.71) .002 Fungal 13 (15) 5 (3) 20 54 (2 64=159.75) 004	Bacterial	11 (12)	2 (1)	10 85 (2 /2_/8 71)	002
	Fungal	13 (15)	5 (3)	20.54 (2.64–159.75)	.002

Table 1. Continued

Clinical Characteristics	Cases n = 85 (%)	Controls n = 169 (%)	OR (95% CI) ^a	<i>P</i> Value ^b
Viral	7 (8)	3 (2)	4.67 (1.21-18.05)	.026
Other	2 (2)	1 (1)	4 (.36–44.11)	.258
Laboratory values at the time of diagnosis				
Median [IQR] white blood cell count (10 ³ /µL)	6.29 (4.42-8.35)	5.915 (4.5-8.6)	.98 (.90–1.07)	.669
Median [IQR] neutrophil count (10 ³ /µL)	3.91 (2.6–6.5)	4 (2.8–6.38)	1.0 (.90–1.11)	.956
Median [IQR] lymphocyte count (10 ³ /µL)	.8 (.45–1.19)	1.2 (.79–1.7)	.25 (.12–.54)	<.001
Median [IQR] aspartate aminotransferase (U/L)	26.5 (19–34.5)	22 (16–27)	1.00 (.99–1.01)	.485
Median [IQR] alanine aminotransferase (U/L)	24 (18.5–34.5)	21 (15–31)	1.01 (.99–1.02)	.245

Abbreviations: BMI, body mass index; CI, confidence interval; CMV, cytomegalovirus; D, organ donor; ICU, intensive care unit; IQR, interquartile range; H2-RAs, histamine H2 receptor antagonists; mTOR, mechanistic target of rapamycin; OR, odds ratio; PPIs, proton pump inhibitors; R, organ recipient.

^aOR and 95% CI from bivariate conditional regression, conditional on matched pairs.

^bP value from Type 3 Wald tests.

^cTransplant type was a matching variable for cases and controls.

^dLimited to comorbidities with a frequency >5 in at least one of the groups.

^ereceived within the 90 days prior to the index date.

^fDoses of different corticosteroids were converted to the equivalent prednisone dose in mg

^gThis included basiliximab (n = 12) or alemtuzumab (n = 4), rituximab (n = 1), and anti-thymocyte globulin (n = 2).

^hSuspected or confirmed organ rejection.

for transplantation and other laboratory values at the time of diagnosis did not differ significantly (Supplementary Table 3 and Table 1).

In the multivariable conditional logistic-regression model, factors associated with a higher likelihood of NTM infection after SOT included receipt of lymphocyte-specific antibodies (adjusted odds ratio [aOR], 7.73; 95% confidence interval [CI], 1.07–56.14; P=.043), receipt of antifungals (aOR, 5.35; 95% CI, 1.7–16.91; P=.004), and prior hospitalization (aOR 3.14; 95% CI, 1.41–6.98; P=.005); all within 90 days of the NTM diagnosis.

Older age was associated with 4% higher likelihood of NTM disease (aOR 1.04; 95% CI, 1.01–1.07; P = .013) and 8% higher likelihood when limited to those with extrapulmonary disease (aOR 1.08; 95% CI, 1.02–1.15; P = .008). In those with extrapulmonary disease, the multivariable model identified receipt of antivirals within 90 days as a factor increasing the likelihood of NTM infection (aOR 56.86; 95% CI, 1.58–2043.41; P = .027). In the multivariable analysis limited to patients with pulmonary disease, hospital admission and prior receipt of antibacterial and antifungal therapy were associated with a higher likelihood of NTM disease (Table 3).

When lymphocyte count was included in the models, higher lymphocyte count was associated with a 75% lower likelihood of NTM disease (95% CI, .12–.55; P < .001), and this association remained significant in the pulmonary (aOR 0.29; 95% CI, .09–.9; P = .032) and extrapulmonary models (aOR 0.28; 95% CI, .1–.84; P = .023) (Table 3 and Supplementary Figure 1).

Pulmonary and Extrapulmonary NTM Disease

In subgroup analysis limited to extrapulmonary NTM disease (n = 36), comorbidities, risk factors, demographic and

transplant characteristics were similarly distributed between cases and controls. Compared to controls, cases had been more frequently hospitalized (28% vs 13%; P = .041) or diagnosed with other infections (25% vs 7%; P = .016) within 90-days of the NTM disease diagnosis, explaining the higher use of antibacterial (66% vs 28%; P < .001) and antiviral therapies (37% vs 15%; P = .015) seen (Supplementary Table 4).

Those with pulmonary disease (n = 49) were more likely to have a concomitant fungal infection (24% vs 5%, OR 9.86; 95% CI, 2.17–44.72; P < .001) or diagnosed with pneumonia (45% vs 14%, OR 7.67; 95% CI, 2.58–22.79; P < .001), 90 days prior to the NTM diagnosis (Supplementary Table 5).

Overall, at the time of diagnosis, median lymphocyte count was lower in patients with both pulmonary (0.9 vs $1.2-10^3/\mu$ L; *P* = .016) and extrapulmonary disease (0.7 vs $1.21-10^3/\mu$ L; *P* = .009) than controls (Supplementary Tables 4 and 5).

DISCUSSION

To the best of our knowledge, this is the first multinational and largest study to explore risk factors for NTM infection in SOT population. NTM infection was significantly associated with older age at the time of transplant, receipt of lymphocyte-specific antibody therapy, prior hospital admission and receipt of antifungal therapy; all within 90 days of the diagnosis. In the general population, older age is a predictor of poor prognosis for NTM-PD [20]; however, this has not been previously described as a risk factor in SOT. Hospitalization and receipt of antifungal therapy within 90 days are likely markers of both delayed NTM disease and/or misdiagnosis; however, 15% of the cases did have a concomitant fungal infection. Delayed diagnosis is common in NTM-PD, yet poorly characterized in the general population

Table 2.	Clinical and Microbiological	Characteristics of Nontuberc	ulous Mycobacterial	Disease in Solid Organ	Transplant Recipients
----------	-------------------------------------	------------------------------	---------------------	------------------------	------------------------------

		Transplant Type				
Characteristics	Overall n = 85 (%)	Lung n=30 (%)	Kidney n=36 (%)	Liver n = 9 (%)	Heart n = 9 (%)	Pancreas n = 1 (%)
Rapid growing mycobacteria	37 (44)	18 (60)	10 (28)	5 (56)	3 (33)	1 (100)
Mycobacterium abscessus complex	18	12	2	1	2	1
Mycobacterium chelonae	8	2	4	1	1	
Mycobacterium fortuitum	9	3	3	3		
Mycobacterium mucogenicum	2	1	1			
Slow growing mycobacteria	48 (56)	12 (40)	26 (72)	4 (44)	6 (67)	
Mycobacterium avium complex	27	9	11	3	4	
Mycobacterium kansasii	8		6		2	
Mycobacterium genavense	5		5			
Mycobacterium haemophilum	2		2			
Mycobacterium xenopi	1	1				
Mycobacterium marinum	1		1			
Mycobacterium celatum	1			1		
Mycobacterium parascrofulaceum	1		1			
Mycobacterium scrofulaceum	1	1				
Mycobacterium gordonae	1	1				
Site of NTM infection						
Pulmonary	49 (58)	26 (87)	12 (33)	5 (56)	5 (56)	1 (100)
Skin and soft tissue	18 (21)	2 (7)	11 (31)	2 (22)	3 (33)	0
Endovascular and disseminated disease	14 (21)	0	11 (31)	2 (22)	1 (11)	0
Other ^a	4 (5)	2 (7)	2 (6)	0	0	0
Median number of positive cultures [IQR]	1 [1–2]	1 [1–2]	1 [1–2]	2 [1–2]	1 [1–1.5]	3
Median time from transplant to culture positivity in months	21.6 [5.3–55.2]	11.3 [4.2– 31 0]	34.7 [17.0– 64.0]	21.6 [3.5–	3.5 [2.9– 67 1]	27.3

Abbreviations: IQR, interquartile range; NTM, nontuberculous mycobacteria.

^aOther sites of infection included one case each of mediastinitis, empyema, colitis, and kidney allograft infection.

[21, 22], and it might impact outcomes as those with NTM-PD who achieve microbiological eradication after six months of therapy have lower mortality risk [23].

Although 1 of the diagnostic criteria for NTM-PD in current guidelines is the exclusion of an alternative diagnosis [24], these criteria have not been validated in SOT recipients. In SOT, a myriad of infections can occur due to the net state of immunosuppression, and fungal infections, commonly aspergillosis, are well-known to increase morbidity and mortality in this population [25], potentially leading to misdiagnosis. Additionally, *Mycobacterium avium* complex and *Aspergillus* species coinfection has been previously reported [26]. Epidemiologically, environmental co-exposure for fungi and Mycobacteria and clinically use of immunosuppressive therapy, are shared risks for both diseases in SOT. This might explain the association of increased of NTM infection and receipt of antifungal therapy seen in this study.

Although, therapy with lymphocyte-specific antibodies in this study included almost exclusively basiliximab or alemtuzumab, which are commonly used as induction therapy and to treat cell-mediated allograft rejection, we found no increased risk of NTM infection in those with prior acute organ rejection, unlike previously described in another study [12]. Nonetheless, the increased likelihood of NTM disease with these agents in the multivariable model is supported by the finding of higher lymphocyte counts being associated with a lower likelihood of NTM disease in the bivariate analysis, and in the predetermined entry multivariable model, where it remained the only factor significantly associated with NTM disease. This finding is biologically plausible, given the increased risk of NTM infection in those with poor T-cell function like severe combined immunodeficiency, advanced human immunodeficiency virus infection, and kidney and liver transplant recipients [27–29].

In keeping with findings from other studies where the median onset of NTM infection in transplant recipient varied widely [12, 30], in this study time to infection ranged from 6 days to 27 years. The higher incidence of lung infection seen compared to other organs is in keeping with the epidemiology of NTM disease in the general population, where around 75% cases are pulmonary [31, 32]. Although over half of those patients with disseminated NTM infection had evidence of lung involvement, none of the lung transplant recipients were diagnosed with disseminated disease, similar to that seen by Huang and colleagues [15]. Furthermore, no case of isolated NTM lymphadenitis was reported, consistent with previous studies that found



Time from transplant to NTM infection

Figure 1. Time from transplant to infection by type of nontuberculous mycobacteria. Abbreviations: NTM, nontuberculous mycobacteria; RGM, rapidly growing mycobacteria; SGM, slow growing mycobacteria.

it to be rare in the absence of disseminated infection [30, 33]. Similarly, yield of mycobacterial blood cultures in disseminated disease was slightly lower than previously reported in in people with human immunodeficiency virus (HIV) [34].

This study has several limitations. First, there is a risk of misclassification of some variables (eg, pneumonia) that could have overlapped with the outcome of NTM diagnosis, potentially leading to erroneous associations of increased risk. To

Table 3. Multivariable Conditional Regression Models of Risk Factors Significantly Associated With Nontuberculous Mycobacterial Disease, Pulmonary, and Extrapulmonary, in Solid Organ Transplant Recipients

Multivariable models with stepwise selection ^a						
	Any NTM Disease (n = 249)		NTM Pulmonary Disease (n = 145)		NTM Extrapulmonary Disease (n = 106)	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	<i>P</i> value
Age at transplant	1.04 (1.01–1.07)	.013			1.08 (1.02–1.15)	.008
Chronic lung/pulmonary circulation disorder ^b			2.23 (.81-6.14)	.12		
Lymphocyte-specific antibodies	7.73 (1.07–56.14)	.043				
Prior antibacterials			5.35 (1.83–15.66)	.002	6.71 (1.72–26.22)	.006
Prior antifungals	5.35 (1.7–16.91)	.004	5.25 (1.33–20.75)	.018		
Prior antivirals					0 56.86 (1.58–2043.41)	.027
Prior hospital admission ^c	3.14 (1.41–6.98)	.005	0.33 (1.12–.93)	.035		
Secondary models ^d						
	Any NTM Disease (n = 185)		NTM Pulmonary Disease (n = 128)		NTM Extrapulmonary Disease (n = 57)	
<u></u>	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	<i>P</i> value
Lymphocyte count (10 ³ /µL)	0.25 (.12–.54)	<.001	0.29 (.09–.9)	.032	0.28 (.1–.84)	.023
Chronic lung/pulmonary circulation disorder ^b			1.56 (.46–5.29)	.473		
Prior antibacterials			3.63 (1.24-10.64)	.019		

Abbreviations: CI, confidence interval; NTM, nontuberculous mycobacteria; OR, odds ratio.

^aModels were generated using a stepwise selection approach with entering in all variables that had ≦5% missing data. Variables were entered into the model with P<.1 and remained in the model if P<.05. OR, 95% CI, and P values are shown only for variables that were included in the final models.

^bChronic lung disease/pulmonary circulation disorder was included into the NTM pulmonary disease models

^cIncludes all admissions within 90 days of the NTM infection diagnosis.

^dModels had lymphocyte count included

minimize this we removed such variables from the multivariable model. Due to the multisite study design there is a risk of diagnostic access bias; thus, we addressed this by using matched pairs from the same center. In addition, despite being the largest case series of NTMs in SOT, the number of patients is still relatively small, likely reflecting the low incidence of NTM infection after SOT [7], especially when strict diagnostic criteria are applied [10]. It could also be due to lack of outbreaks during the study period at the participating centers. However, it might represent under diagnosis of NTM infection due to a low index of suspicion. The study design did not allow us to calculate incidence rates. Moreover, the inclusion of multiple centers from several countries reflects a wide environmental epidemiology and broad scope of medical management. Finally, missing data might have limited the precision of the estimates and increased the likelihood of bias. However, to minimize potential bias that can result from analyzing variables with high rates of missingness, we only considered variables with <5% missing data in the multivariable models, with the exception of lymphocyte count.

In conclusion, this is the first multinational study describing clinical characteristics and risk factors for NTM after SOT. Risk of NTM infection after SOT was associated with older age at the time of transplant, and hospital admission, receipt of antifungals or lymphocyte-specific antibodies; all within 90 days of the diagnosis. Higher risk of NTM disease in those with lymphopenia warrants further investigation. Our study provides relevant information to clinicians about the context in which NTM infection occurs. An international prospective NTM registry in SOT could help identify predictors to establish an early diagnosis for these uncommon infections.

Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. This study was performed in collaboration with the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC), the Study Group for Infections in Compromised Hosts (ESGICH) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Swiss Transplant Cohort Study (STCS). We thank the Vancouver Costal Health Research Institute and BC Transplant for providing the data as well as the lung transplant clinic at Vancouver General Hospital, and the kidney transplant clinic at St. Paul's hospital.

Financial support. This work was not supported by any external funding agency in the public, commercial, or not-for-profit sectors. N. J. M. reports support for this work from Swiss National Science Foundation for funding for data collection, paid to the institution. C. G. reports funding for this work provided by the Division of Infectious Diseases, Washington University School of Medicine in St. Louis.

Potential conflicts of interest. C. M. C. reports the following grants or contracts unrelated to this work: Centers for Disease Control and Prevention (CDC) subaward from Johns Hopkins University to the Washington University in St. Louis (funding by the CDC grant number 1U54CK000617-01-00), vendor/individual agreement with Wayne State University for a case registry, and Associate Editor for Open Forum Infectious Diseases (1 May 2022 through 30 April 2023). D. F. P. reports payment or honoraria as a speaker for an antibiotic course for UMC Utrecht and as a teacher for Hospital Pharmacists in training for PAO; and participation on DSMB for the COBRA trial (Very short-course versus standard course antibiotic therapy in patients with acute Cholangitis after adequate endoscopic biliaRy drainage) in the Netherlands. M. J. M. reports consulting fees from Insmed and Biomerieux; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing or educational events from Microsoft Diagnostics (MSD), Insmed, and Teva; support for attending meetings and/or travel from MSD, Berlin Chemie; and participation on a Data Safety Monitoring Board or Advisory Board for Biomerieux, Insmed, MSD. J. T. S. reports payment or honoraria for manuscript writing for Gilead on subjects not related to this manuscript. M. B. reports support from Pfizer for attending a congress. N. K. reports royalties or licenses from Up To Date; consulting fees from Astellas, AstraZeneca, Biotest, ExeViR, Hansa, Merck Sharp and Dohme, Glasgow Smith Kline, Novartis Pharma, Takeda; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing or educational events from Astellas, Biotest, CSL Behring, Chiesi, Novartis Pharma, Sanofi, Sandoz, Takeda; and support for attending meetings and/or travel from Astellas, Novartis Pharma, Takeda. N. J. M. reports support for attending meetings and/or travel paid to author from Biotest; unpaid participation on a Data Safety Monitoring Board or Advisory Board for a CTX3 Study and paid participation on Advisory Boards for Takeda, MSD, and Pfizer. N. M. T. reports payment or honoraria for guest lecture for Boston Medical Center and Beth Israel Medical Center; payment for expert testimony for record review for Ficksman & Conley, LLP, in Boston, Massachusetts; participation on a Data Safety Monitoring Board or Advisory Board for United Network for Organ Sharing HIV Organ, Policy Equity (HOPE) Act Safety Review, and Workgroup (unpaid); role as Chair of the American Society of Transplantation and leadership or fiduciary role with Infectious Diseases Community of Practice (unpaid). O. M. reports payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing or educational events from MSD; and participation on a Data Safety Monitoring Board or Advisory Board for MSD. S. Be. reports grants or contracts unrelated to this work from Vancouver Costal Health Research Institute and Transplant Research Foundation of BC; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing or educational events from Merck; and participation on an Advisory Board for Evusheld (AstraZeneca). All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

- 1. Swenson C, Zerbe CS, Fennelly K. Host variability in NTM disease: implications for research needs. Front Microbiol **2018**; 9:2901.
- Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008–2015. Ann Am Thorac Soc 2020; 17:178–85.
- Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012; 185:881–6.
- Ratnatunga CN, Lutzky VP, Kupz A, et al. The rise of non-Tuberculosis mycobacterial lung disease. Front Immunol 2020; 11:303.
- Lake MA, Ambrose LR, Lipman MC, Lowe DM. "Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. BMC Med 2016; 14:54.
- Roberts MB, Fishman JA. Immunosuppressive agents and infectious risk in transplantation: Managing the "net state of immunosuppression." Clin Infect Dis 2021; 73:e1302–17.

- Longworth SA, Daly JS, AST Infectious Diseases Community of Practice. Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13588.
- Shah SK, McAnally KJ, Seoane L, et al. Analysis of pulmonary non-tuberculous mycobacterial infections after lung transplantation. Transpl Infect Dis 2016; 18: 585–91.
- Abad CL, Razonable RR. Non-tuberculous mycobacterial infections in solid organ transplant recipients: an update. J Clin Tuberc Other Mycobact Dis 2016; 4:1–8.
- George IA, Santos CA, Olsen MA, Bailey TC. Epidemiology and outcomes of nontuberculous mycobacterial infections in solid organ transplant recipients at a midwestern center. Transplantation 2016; 100:1073–8.
- Knoll BM, Kappagoda S, Gill RR, et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis 2012; 14:452–60.
- Longworth SA, Vinnard C, Lee I, Sims KD, Barton TD, Blumberg EA. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. Transpl Infect Dis 2014; 16:76–83.
- 13. Katsolis JG, Keller CA, Alvarez F, et al. Nontuberculous mycobacterial infections after lung transplantation: risk factors and impact on graft survival and mortality in the era of improved detection. 49th Annual Meeting of the Infectious Disease Society of America 2011.
- Friedman DZP, Cervera C, Halloran K, Tyrrell G, Doucette K. Non-tuberculous mycobacteria in lung transplant recipients: prevalence, risk factors, and impact on survival and chronic lung allograft dysfunction. Transpl Infect Dis 2020; 22: e13229.
- Huang HC, Weigt SS, Derhovanessian A, et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant 2011; 30:790–8.
- Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367–416.
- Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017; 72:ii1–64.
- Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019; 95: 103208.
- 19. Furuuchi K, Fujiwara K, Uesgi F, et al. Posttreatment lymphopenia is associated with an increased risk of redeveloping nontuberculous lung disease in patients with *Mycobacterium avium* complex lung disease. Clin Infect Dis **2021**; 73: e152–7.

- Andrejak C, Thomsen VO, Johansen IS, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010; 181:514–21.
- Jing H, Tan W, Deng Y, et al. Diagnostic delay of pulmonary nontuberculous mycobacterial infection in China. Multidiscip Respir Med 2014; 9:48.
- Ryu YJ, Koh WJ, Daley CL. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians' perspectives. Tuberc Respir Dis (Seoul) 2016; 79:74–84.
- Im Y, Hwang NY, Kim K, Kim H, Kwon OJ, Jhun BW. Impact of time between diagnosis and treatment for nontuberculous mycobacterial pulmonary disease on culture conversion and all-cause mortality. Chest 2022;161:1192–200.
- Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 2020; 56:2000535.
- Phoompoung P, Herrera S, Perez Cortes Villalobos A, Foroutan F, Orchanian-Cheff A, Husain S. Risk factors of invasive fungal infections in liver transplant recipients: a systematic review and meta-analysis. Am J Transplant 2022;22:1213–29.
- Joao I, Bujdakova H, Jordao L. Opportunist coinfections by nontuberculous mycobacteria and fungi in immunocompromised patients. Antibiotics (Basel) 2020; 9:771.
- Abe Y, Fukushima K, Hosono Y, et al. Host immune response and novel diagnostic approach to NTM infections. Int J Mol Sci 2020; 21:4351.
- Fernandez-Ruiz M, Lopez-Medrano F, Allende LM, et al. Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation. Transpl Int 2014; 27:674–85.
- Fernandez-Ruiz M, Lopez-Medrano F, Romo EM, et al. Pretransplant lymphocyte count predicts the incidence of infection during the first two years after liver transplantation. Liver Transpl 2009; 15:1209–16.
- Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 1994; 19:263–73.
- Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009; 49:e124–9.
- Hermansen TS, Ravn P, Svensson E, Lillebaek T. Nontuberculous mycobacteria in Denmark: incidence and clinical importance during the last quarter-century. Sci Rep 2017; 7:6696.
- Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38:1428–39.
- 34. MacGregor RR, Hafner R, Wu JW, et al. Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study. AIDS Res Hum Retroviruses 2005; 21:689–95.